To elucidate the mechanism underlying suppression of N-nitrosobis(2-oxopropyl)amine (BOP)-induced hamster pancreatic carcinogenesis by cigarette smoke (CS), hepatic levels of microsomal cytochrome P450 (CYP) enzymes, mutagenic activation of environmental carcinogens and three types of uridine diphosphate-glucuronyltransferase (UDPGT) and sulphotransferase (ST) activities were assayed in male Syrian golden hamsters and F344 rats exposed to CS. Immunoblot analyses of microsomal CYP proteins revealed induction of constitutive CYP1A2 (2.6-fold increase) and 2A8 (4.0-fold increase) and induction of CYP1A1 and constitutive CYP1A2 (3.9-fold increase) in rats following exposure to CS for 4 weeks using a Hamburg type II smoking machine. CS exposure enhanced mutagenicities of four heterocyclic amines in the presence of liver S9 in both species, whereas the mutagenicities of aflatoxin B 1 (AFB 1 ), 2-amino-3-methyl-9H-pyrido [2,3-b]indole (MeAaC) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) were significantly increased by CS in hamsters but not in rats. However, no CS-induced alterations in the mutagenic activities of other carcinogens, including BOP and other pancreatic carcinogens, were observed in either species. Application of several CYP inhibitors revealed that the mutagenic activities of MeAaC, AFB 1 and NNK in the hamster liver S9 were partly associated with CYP2A8, whereas those of the three pancreatic carcinogens were selectively associated with CYP2B. CS enhanced UDPGT activities towards 4-nitrophenol (4-NP) (1.9-to 2.0-fold) but did not affect those of bilirubin, testosterone UDPGTs and three STs in both species. Together with the previous findings that BOP does not induce tumourigenesis in rats and that the glucuronidation of b-oxypropylnitrosamines is higher in rats than in hamsters, suppression of BOP-induced pancreatic carcinogenesis by CS might be attributed to increased detoxification by 4-NP UDPGT and not decreased CYP2B activation. This is the first demonstration of the induction of CYP2A protein by CS; CYP2A protein polymorphisms have been associated with oral and pulmonary carcinogenesis in smokers.
Introduction
Lifestyle factors are considered major risk factors in human cancers and cigarette smoking contributes to $30% of such diseases (1) . Epidemiological studies have suggested that cigarette smoking is closely associated with an increased risk of cancers in various organs such as the lungs, urinary tract, oral and nasal cavity, paranasal sinuses, nasopharynx, oropharynx, hypopharynx, oesophagus, larynx, pancreas, stomach, liver and cervix (2) . However, attempts to induce lung or other cancers in experimental animals by inhalation of cigarette smoke (CS) have mostly been unsuccessful (3) , indicating that CS is not a potent carcinogen per se. Therefore, the effects of CS may be explained in terms of its modifying effects on endogenous and exogenous carcinogens. In fact, it has been shown that CS increases the incidence of upper respiratory tract tumourigenesis in hamsters initiated with N-nitrosodiethylamine (DEN) (4) and hepatocarcinogenesis in rats initiated with 2-amino-3,8-dimethylimidazo [4,5- f]quinoxaline (MeIQx) (5) . However, we found that CS exposure inhibits pancreatic carcinogenesis induced by N-nitrosobis(2-oxopropyl)amine (BOP) when given in the initiation phase in Syrian golden hamsters (6) . CS contains various chemopreventive agents such as antioxidants (7) , cembrane-type diterpenes (8) , carotenoids and polyphenol (9) . CS condensate and its constituents are reported to exhibit anti-mutagenicity (10, 11) . However, to our knowledge, no data have been provided on the mechanism of the CS-inducing chemopreventive effect on carcinogenesis.
Carcinogenic N-nitroso compounds (NOCs), including BOP, require metabolic activation to elicit their carcinogenic effects. Cytochrome P450 (CYP) 2A, 2B and 2E play important roles in this activation. CYP2E1 predominantly activates N-nitrosodimethylamine and DEN (12) , whereas CYP2B (13, 14) and CYP2A (15) activate NOCs possessing relatively long alkyl chains. We have demonstrated that N-nitrosobis(2-hydroxypropyl)amine (BHP) and N-nitroso(2-hydroxypropyl) (2-oxopropyl)amine (HPOP), presumed proximate carcinogenic metabolites of BOP, are mutagenetically activated by phenobarbital-inducible CYP2B species (13) but the involvement of CYP2A in metabolic activation of BOP-related NOCs has not been clarified. BOP and BOP-related NOCs produce pancreatic carcinogenesis in hamsters but not in rats (16) . The most definite difference between hamsters and rats in the metabolism of BOP-related NOCs are observed in UDPglucuronic acids and 3#-phosphoadenosine-5#-phosphosulphate conjugates; the glucuronidation of b-oxypropylnitrosamines is higher in rats than in hamsters and vice versa for sulphation (17) (18) (19) .
CS is known to induce hepatic CYP1A2 in smokers (20) and rodents (21) (22) (23) . We observed that CS exposure also induced CYP1A1 in the rat liver but not in the hamster liver (23, 24) . Further, CS induction of hepatic CYP2B, 2E1 or 3A proteins and metabolic activities specific to these CYP proteins has been reported in rats (25) and mice (26) . CS enhancement of MeIQx-induced hepatocarcinogenesis in F344 rats can be attributed to an increase in metabolic activation of MeIQx by hepatic CYP1A2 (24) . The tobacco-specific NOC 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is mainly activated by CYP2A in rats (27, 28) , mice (29) and humans (15) . CYP2A6 gene deletion due to genetic polymorphism was reported to reduce lung cancer risk among tobacco smokers in a case-control study of Japanese subjects (30) and oral cancer risk in betel quid chewers in Sri Lanka (31) . However, no studies have been reported on the influence of CS on CYP2A expression and its metabolic activity in any animal species. Meanwhile, CS is known to induce hepatic uridine diphosphate-glucuronyltransferase (UDPGT) 1A6 activity in rats (24) , mice (32) and humans (33) , suggesting that CS induces inactivation of carcinogens by glucuronidations. In the rat liver, UDPGTs towards bilirubin, 4-nitrophenol (4-NP) and testosterone are found as major enzymes (34) and UDPGT2B1 is suggested to be the probable enzyme responsible for glucuronidation of DEN and N-nitrosomethyl-npentylamine (35) . In rat, three major sulphotransferase (ST) isozymes catalyse sulphation of phenol (aryl ST, activity towards 4-nitrophenol at pH 5.5 or 6.5) or alcohol [hydroxylsteroid ST, activity towards dehydroepiandrosterone (DHEA)]. CS extract is reported to inhibit human ST activities in HepG2 cells (36) , and ST2A2 mRNA in the rat liver expression is reported to be markedly suppressed by a CYP1A inducer, 3-methylcholanthrene (3-MC) (37) . DHEA sulphate, a hydroxysteroid ST (ST2A) inhibitor, significantly suppresses BOP-induced pancreatic carcinogenesis in hamsters (38) . Accordingly, CS might inhibit the carcinogenic activation of BOP by enhancing glucuronidation or suppressing sulphation. However, no data have been provided regarding the effect of CS on these three UDPGT activities in the hamster liver or on the three ST activities in the livers of either hamsters or rats.
To elucidate the mechanism(s) underlying the suppression of BOP-induced hamster pancreatic carcinogenesis by CS, hepatic levels of microsomal CYP enzymes known to activate typical environmental carcinogens, mutagenic activation of these carcinogens by the liver S9 as well as coumarin 7-hydroxylase (COH) activity and each of the three types of UDPGT and ST activities were assayed in hamsters treated with sham smoke (SS), SS þ BOP and CS þ BOP. We also report on the CYP species responsible for metabolic activation of three carcinogens showing hamster-specific activation by CS and three BOP-related NOCs.
Materials and methods

Chemicals
Acetates of 3-amino-1-methyl-5H-pyrido [4,3-b] indole (Trp-P-2) and 2-amino-3-methyl-9H-pyrido [2,3-b] indole (MeAaC), hydrochlorides of 2-amino-6-methyldipyrido[1,2-a:3#,2#-d]imidazole (Glu-P-1) and 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP), 2-amino-3-methylimidazo [4,5- . All other commercial products were of the purest grade available. BHP, BOP, HPOP and N-nitroso-2,6-dimethylmorpholine (NDMM) were synthesised in our laboratory as described previously (13) . Non-filter cigarettes were obtained from Japan Tobacco (Tokyo, Japan).
Animal treatment and tissue preparation
All animal experiments were undertaken following guidelines for the care and use of experimental animals set by Gifu Pharmaceutical University and the National Institute of Health Sciences. Twenty male 5-week-old Syrian golden hamsters and F344 rats purchased from Sankyo Labo Service (Tokyo, Japan) were housed in groups of five in plastic cages and maintained under standard laboratory conditions. Both species were divided into three groups and were given CS and BOP (Figure 1 ). Hamsters and rats in Group 1, five of each species were exposed to SS for 4 weeks. The five hamsters and five rats in Group 2 were administered subcutaneously BOP 10 mg/kg once a week for 3 weeks and were simultaneously exposed to SS for 4 weeks. The 10 animals (5 of each species) in Group 3 were simultaneously exposed to BOP and CS for 4 weeks. Hamsters in Group 3 were exposed to the smoke of 30 cigarettes for 9 min, twice a day, 5 days a week using a Hamburg type II smoking machine (Borgwaldt, Hamburg, Germany); rats were exposed to the smoke generated under the same condition for 6 min, once a day. The smoke was generated under the following conditions: inhalation volume, 35 ml; inhalation flow, 17.5 ml/sec and dilution of CS, 1/7 (23). The SS treatment involved restricting animals to a chamber of the smoking machine under the same conditions as that of the CS treatment but without smoke. All animals were immediately decapitated after the last CS exposure. Livers were perfused in situ with ice-cold sterile 1.15% KCl and 25% homogenates in 1.15% KCl were prepared. The liver S9 and microsomes were prepared using established procedures (13) .
Western blots
Goat anti-rat polyclonal antibodies for CYP1A1/2, CYP2B1/2 and CYP2E1, rabbit anti-rat CYP3A2 (Nosan Co., Yokohama, Japan) and goat anti-human polyclonal antibodies for CYP2A (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used as the primary antibodies. Gel electrophoresis and blot analysis were performed as described previously (23) .
Mutation assay
All tests were performed using the Ames pre-incubation assay (39). NOCs were dissolved in 100 ll of water and all the other carcinogens in 50 ll of dimethyl sulphoxide. The mutagenicities of Trp-P-2, Glu-P-1 and IQ (dose, 0.03 lg/ plate), MeAaC (10 lg), PhIP and BP (5 lg), AFB 1 (1 lg), NNK (0.5 mg) and the other NOCs (10 mg) were checked in the presence of liver S9 using established procedures (13, 28) . The liver S9 fraction was 10 ll/plate for the heterocyclic amines (HCAs), 50 ll for BP and NNK and 150 ll for the other NOCs and AFB 1 . Salmonella typhimurium tester strain TA100 was used for the NOCs and strain TA98 for the other carcinogens. The liver S9 mix contained 4 mM NADPH, 4 mM NADH, 0.5 U G6PDH, 5 mM G6P and 5 mM ATP; however, for NOCs, 4 mM NADP þ and 5 mM G6P were used. In the CYP inhibition experiments, 0.1 mM 4-methylpyrazole, 0.2 mM furafylline and 7,8-BF, 1 mM metyrapone (28) and 25 lM methoxsalen (40) were pre-incubated with carcinogen substrate and the liver S9 mix.
Assay of enzymatic activity COH activity in the liver microsomes was assayed according to the method described by Juvonen et al. (41) . UDPGT activities towards bilirubin and 4-NP in the liver microsomes were assayed according to the methods described by Heirwegh et al. (42) and Isselbacher et al. (43) , respectively, and UDPGT activity towards testosterone was determined using UDP-[ 14 C(U)]glucuronic acid as described by Matern et al. (44) . Aryl ST and hydroxysteroid ST activities towards 4-NP and DHEA in the liver cytosols were assayed according to the methods described by Sekura et al. (45, 46) and Nose and Lipmann (47), respectively. 
Statistical analysis
Statistical analyses by Student's t-test were performed to determine the significance of any differences between groups. All statements of significance are P , 0.01.
Results
Just after CS exposure, animals show tiredness, decreasing activities, mild dehydration, bad coating, and so on. However, these symptoms were not so severe and disappeared after a few hours. Body weight gain slightly but significantly delayed in Group 3 compared with other two groups from Day 28 in hamsters (97.1 AE 3.0 g versus 111.3 AE 3.7 g and 110.7 AE 2.4 g) or rats (149.3 AE 2.3 g versus 160.4 AE 9.1 g and 160.1 AE 10.3 g). But other constitutive clinical sign was not observed during the experimental period. Figure 2 shows immunoblots and levels (picomoles per milligram protein) of microsomal CYP proteins in Syrian golden hamsters or F344 rats treated with SS, BOP þ SS or BOP þ CS for 4 weeks. CYP proteins in the hamster liver were positively detected with antibodies against rat CYP1A1/2, 2B1/ 2, 2E1 and 3A2 and human CYP2A. Treatment with BOP þ SS in Group 2 hamsters produced no significant effect on the expression of CYP1A2. In contrast, the CYP1A2 level in Group 3 hamsters (BOP þ CS treatment) was 2.6-fold higher (P , 0.01) than that in SS-treated hamsters (Group 1). On the other hand, CYP1A1 protein was not detected in any group of hamsters. Hepatic CYP2A8 was constitutively detected in the liver microsomes from Group 1 hamsters and migrated slightly slower than the standard CYP2A6. The constitutive CYP2A8 was not increased in Group 2 but was 2.7-fold higher in Group 3 compared to Group 1. No significant differences were observed in the hepatic levels of 53-and 55-kDa proteins detected with the anti-rat CYP2B1/2 antibody, CYP2E1 and CYP3A10 among the three hamster groups. Meanwhile, CYP1A1 protein was induced in Group 3 rats and the constitutive CYP1A2 level was 3.9-fold higher (P , 0.01) in Group 3 rats than in Group 1 rats. The enhancement of rat CYP1A2 was 4.9-fold that of CYP1A1. In contrast, BOP þ SS treatment in Group 2 produced no significant effect on the expression of CYP1A1 and 1A2. Anti-human CYP2A also detected rat CYP2A1/2 but no significant alterations were observed in these proteins. CYP2B1 was not constitutively expressed and was not induced in any group of rats and no significant differences in hepatic levels of CYP2B2, 2E1 and 3A2 proteins among the three rat groups were observed. To confirm the induction of CYP2A8 by CS exposure, COH activity was assayed in liver microsomes from hamsters and rats in the three groups. As shown in Figure 3 , COH activity in Group 1 hamsters (74.3 AE 4.1 pmol/min/mg protein) was 5.7-fold higher than that in Group 1 rats (13.0 AE 3.8 pmol/min/mg protein). The activity in Group 3 hamsters was significantly increased by 2.5-fold relative to that in Group 1 hamsters, while no enhancement was observed in Group 2 hamsters or in the three groups of rats.
To clarify the mutagenic activation induction characteristics of CS, 13 carcinogens that are known to be metabolically activated by specific CYP species were assayed using S.typhimurium strains TA98 and TA100. Figure 4A shows the mutagenic activities of five HCAs, BP, AFB 1 and six NOCs in the presence of liver S9 from hamsters in Groups 2 and 3. The numbers of revertant colonies per plate after subtraction of spontaneous rates (TA98, 27; TA100, 126) with the liver S9 from the Group 1 hamsters were 115 AE 26 (means AE SD) for Glu-P- 
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623 AE 117 for DEN in strain TA100. Mutagenic activities of all five HCAs in Group 3 hamsters were significantly increased from 1.7-to 4.1-fold relative to those in Group 1 hamsters; AFB 1 and NNK mutagenic activities were also increased by 1.4-and 2.1-fold, respectively. On the other hand, no significant alterations in mutagenicity were observed with BP, BOP, BHP, HPOP, NDMM or DEN in Group 3 hamsters or with all the carcinogens tested in Group 2 hamsters. The results of the mutagenic activities in the rat liver S9 are shown in Figure 4B . The numbers of revertant colonies per plate after subtraction of spontaneous rates (TA98, 27; TA100, 126) with the liver S9 in the Group 1 rats were 82 AE 6 for Glu-P-1, 230 AE 40 for IQ, 194 AE 30 for PhIP, 97 AE 15 for Trp-P-2, 285 AE 45 for MeAaC, 287 AE 34 for BP and 2483 AE 258 for AFB 1 in strain TA98 and 101 AE 17 for NNK, 349 AE 36 for BOP, 179 AE 27 for BHP, 258 AE 33 for HPOP, 504 AE 55 for NDMM and 396 AE 43 for DEN in strain TA100. The liver S9 from Group 3 rats increased the mutagenic activities of four HCAs from 2.0-to 2.9-fold above that of Group 1 rats but did not alter MeAaC, BP, AFB 1 or the five NOCs including NNK. BOP treatment in Group 2 rats exerted no significant effect on the mutagenic activities of all of these carcinogens.
To confirm the extent of participation of each hamster CYP species in mutagenic activation of MeAaC, AFB 1 and NNK, selective CYP inhibitors were pre-incubated with the liver S9 from Group 3 hamsters. As shown in Figure 5A and B, the CYP1A inhibitor 7,8-BF inhibited 86% of the mutagenic activation of MeAaC and AFB 1 , and the CYP2A inhibitor methoxsalen inhibited up to 60% of these activities. The selective CYP1A2 inhibitor furafylline showed a slight but significant inhibition (28%) of the mutagenic activity of AFB 1 but not MeAaC. The mutagenic activity of NNK was inhibited 86, 45, 65 and 47% by 7,8-BF, furafylline, methoxsalen and the CYP2B inhibitor, metyrapone, respectively, while no significant variation in the presence of the CYP2E1 inhibitor 4-methylpyrazole ( Figure 5C ) was observed. In an attempt to obtain more information about the CYP species responsible for activation of the three pancreatic carcinogens, selective CYP inhibitors were used in the mutagenic activation assays. Figure 6 shows the effect of three inhibitors specific for CYP2A, 2B and 2E1 on the mutagenic activities of the three BOP-related pancreatic carcinogens BHP, HPOP and NDMM in the presence of liver S9 from hamsters treated with BOP þ CS. Metyrapone inhibited the mutagenic activities of BHP, HPOP and NDMM by up to 46, 61 and 68%, respectively, while methoxsalen and 4-methylpyrazole showed no significant inhibition. Table I summarises the effects of the BOP and CS treatments on the three types of UDPGT activities in the presence of liver microsomes from hamsters. Testosterone UDPGT activities in Group 1 hamsters were higher than those in Group 1 rats but the other two UDPGTs were almost the same between the two species. No significant differences were observed in the Fig. 4 . Testing of mutagenic activities of various carcinogens using S.typhimurium strain TA98 (HCAs, BP and AFB 1 ) and TA100 (NOCs) in the presence of liver S9 from hamsters (upper) or rats (lower) treated with SS, BOP þ SS or BOP þ CS. Each test was performed in duplicate (four to eight plates) with the liver S9 pooled from five hamsters each treated with BOP þ SS (lightly stippled) or BOP þ CS (hatched). The activities represent the mean AE SD of the ratio to the mutagenic activity obtained with the SS group. *P , 0.01 compared with the SS group (Student's t-test). UDPGT activities towards bilirubin and testosterone among the three groups of hamsters and rats. On the other hand, activity towards 4-NP in hamsters and rats treated and rats with BOP þ CS (Group 3) was increased 1.9-to 2.0-fold above the SS control (Group 1). ST activities towards 4-NP (pH 5.5 and 6.5) and DHEA were performed in the liver cytosols from the three groups of hamsters and rats. ST activities towards 4-NP (pH 5.5) were higher in Group 1 hamsters relative to Group 1 Each test was carried out with liver microsomes pooled from five animals. The results are expressed as means AE SD of four to eight experiments. Values in parentheses show the ratio to the activity obtained with each SS group. *P , 0.01 compared with each SS group.
The effect of CS on mutagenic activation rats (hamsters; 0.61-0.75 nmol/mg protein/min, rats; 0.18-0.22 nmol/mg protein/min), while those towards DHEA were much higher in Group 1 rats (hamsters; 0.22-0.24 nmol/mg protein/min, rats; 1.04-1.20 nmol/mg protein/min). Treatment with BOP þ SS or BOP þ CS in both species produced no significant alterations in the three ST activities.
Discussion
No significant alterations in the hepatic levels of constitutive CYP proteins and mutagenic COH, UDPGT and ST activities were produced by treatment with BOP þ SS. Therefore, the alterations observed in hamsters or rats treated with BOP þ CS are considered attributable to CS exposure alone. In fact, the degree of CYP1A2 induction in Group 3 hamsters and CYP1A1/2 induction in rats is almost the same as that which occurs when both animals are exposed to CS for 2 weeks (23). CYP2A8 is a 57.3-kDa protein that is part of the major CYP2A subfamily expressed in the hamster liver, while CYP2A1 and 2A2 are constitutively expressed in the male rat liver. Therefore, the protein detected by goat anti-human CYP2A antibody was identified as CYP2A8 in the hamster liver microsomes and CYP2A1/2 in the rat liver microsomes. CYP2A8, but not CYP2A1/2, was significantly increased following CS exposure, supporting the results of the induction of hepatic COH activity by CS. To our knowledge, this is the first demonstration of the induction of a CYP2A protein by CS in any animal species. Recently, it was reported that inhalation of CS triggers activation of the aryl hydrocarbon receptor (AhR)-xenobiotic response element (XRE) pathway, which is an important modulator of CYP1 expression (48) . In the hamster liver, the region upstream of the CYP2A8 gene contains a positive regulatory element motif, which potentiates the activation of XRE (49) . In conjunction with the findings that it is not CYP1A1 but CYP2A8 that is the major form induced by 3-MC-type inducer (50) , selective CS induction of CYP1A2 and 2A8, but not of CYP1A1, in the hamster liver might be due to the AhR-XRE pathway activation. The NF-E2 p45-related factor (NRF2) regulates the transcription of several phase II enzymes including UDPGT. The NRF2 expression is also transcriptionally regulated by the AhR-XRE signalling pathway (51), supporting our result that 4-NP UDPGT activity was induced in hamsters and rats exposed to CS. Therefore, CS might enhance both metabolic activation and inactivation via the AhR and NRF2 pathways and further investigations are required to elucidate the contributions of these pathways. CS had no effect on the levels of CYP3A2 in rats and CYP2B and CYP2E in both the species in accordance with the previous findings (23, 24) . However, there are a few reports that hepatic CYP2B in rats (25) and hepatic CYP2E1 and 3A11/13 in mice (22, 26) are clearly induced by CS. The reasons for these discrepancies with regards to CSinducible CYP species are not clear but it is suggested that the differences might in part be due to experimental conditions. CS enhanced the mutagenic activation of four HCAs except for MeAaC by the liver S9 from hamsters and rats, supporting our previous observations (23, 24) . These enhancements were performed by selective induction of hepatic CYP1A species, especially CYP1A2. The mutagenicities of MeAaC and BP, which are predominantly activated by CYP1A1, in the presence of the rat liver S9 were not enhanced by CS. The failure to observe any enhancement might be due to insufficient induction of the CYP species responsible. Mutagenic activities of BP were significantly elevated by the liver S9 from rats treated with Nbenzylimidazole, which is a strong CYP inducer, including CYP1A1 (28) . On the other hand, CS enhanced the mutagenic activity of MeAaC in the presence of liver S9 from hamsters exposed to CS for 4 weeks even though in the hamsters CYP1A1 was not induced. The activity of MeAaC was markedly inhibited by methoxsalen and 7,8-BF but not by furafylline. 7,8-BF is known to mainly inhibit the activities of not only CYP1A1/2 but also CYP2A (52) . Therefore, the enhancing effect of CS on the mutagenic activation of MeAaC is at least in partly performed by elevating CYP2A8 level. It has been reported that 3-MC-inducible CYP2A8 has a potent capacity for activating mutagenicity of AFB 1 , $170-fold higher than that of CYP1A2 (50) . We have demonstrated that mutagenic activation of AFB 1 is not associated with hepatic rat CYP1A2 (28) , suggesting that hamster CYP1A2 is not likely to be involved in this activation. Together with the potent inhibition by 7,8-BF rather than methoxsalen, mutagenic activation of MeAaC and AFB 1 may mainly be attributed to CYP2A8 in the hamster liver. NNK is a specific NOC occurring in CS and this metabolic activation is mainly associated with CYP1A, 2A, 2B and 2E (53) (54) (55) (56) . The inhibition test indicated the involvement of CYP1A2, 2A8 and 2B in mutagenic activation of NNK in the presence of the hamster liver. Several reports suggest that CYP2E1 does not play a key role in NNK activation (15, 28, 57) and that NNK and N-nitrosomethylbenzylamine with its bulky side group are mutagenetically activated by CYP2B1/2 and not CYP2E1 (58) . Therefore, it seems reasonable that the CYP2E1 inhibitor 4-methylpyrazole could not inhibit the mutagenic activity of NNK.
The mutagenic activities of DEN and four pancreatic carcinogens were not induced by CS in the presence of liver S9 from hamsters, reflecting no changes in the levels of CYP2E1 and 2B proteins. Similarly, the activities of BHP, HPOP and NDMM with the liver S9 from hamsters exposed to CS were markedly inhibited by metyrapone, but not by methoxsalen and 4-methylpyrazole, indicating the contribution of CYP2B, but not CYP2A8 and 2E1, to the mutagenic activities of BOP-related carcinogens. Glucuronidation enhances the excretion of these carcinogens resulting in decreased carcinogen DNA interaction and carcinogenesis. HPOP (19) , N-hydroxy-HCAs (59) and a major metabolite of NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butabol (60,61) are known to be substrates for UDPGTs. Hepatic 4-NP UDPGT activity was clearly increased in hamsters and rats exposed to CS, indicating the detoxification by CS of environmental carcinogens. This induction is in line with previous findings in smokers (33) , mice (32) and rats (24) . Glucuronidation of HPOP by the rat liver is reported to be clearly higher than that by the hamster liver both in vivo and in vitro (19) and is associated with the species difference in BOP-induced pancreatic carcinogenesis between hamsters and rats (16) . Together with the contribution of UDPGT1A species to NOC (60, 61) , glucuronidation of NOCs is critical in detoxification and CS may suppress BOP-induced carcinogenesis partly through induction of hepatic 4-NP UDPGT activity. BOPinduced pancreatic carcinogenesis is suppressed by DHEA sulphate, a hydroxysteroid ST (ST2A) inhibitor (38) , and 3-MC markedly reduces the level of ST2A2 mRNA in the rat liver (37) . These findings suggest that ST2A2 candidate enzymes suppress BOP-induced carcinogenesis by CS. However, no significant differences were observed in the three ST activities including DHEA ST following CS exposure for 4 weeks in either species. Epidemiological studies have revealed that genetic polymorphism of human sulphotransferase 1A1 is associated with squamous cancer (62) . Therefore, further investigation is required to elucidate the effect of CS on sulphotransferase expression and activities.
In conclusion, the present study has demonstrated that CS increases CYP1A2 and 2A8 levels and enhances mutagenic activation of HCAs, including MeAaC, AFB 1 and NNK, and 4-NP UDPGT activity in hamsters. Together with the contribution of CYP2B to the mutagenic activation of BOP-related NOCs, it is suggested that suppression of BOP-induced pancreatic carcinogenesis in hamsters exposed to CS might be attributed to increased detoxification by 4-NP UDPGT and not to decreased activation by CYP2B. Further, this is the first study to demonstrate that CS induces CYP2A species known to play an important role in lung and oral cancers among smokers (30, 31) , suggesting that the hamster is a suitable animal species for studying CS-induced carcinogenesis. Further, CS might enhance carcinogenesis induced by NNK, AFB 1 and MeAaC in hamsters through induction of CYP2A species. These results show that CS is a bifunctional inducer and a double-edged sword since it has both enhancement and suppression effects on carcinogenesis. Further investigation into the modifying effect of CS on carcinogenesis induced by Glu-P-1 or PhIP activated by CYP1A and inactivated by UDPGT should be conducted.
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